Becker's Healthcare November 16, 2023
The FDA and CDC are working to deploy more Beyfortus doses as its maker underestimated demand for the first respiratory syncytial virus drug approved for children.
On Nov. 16, the CDC said it released 77,000 Beyfortus (nirsevimab-alip) intramuscular injection solutions, which are being sent to physicians and hospitals through commercial channels and the CDC’s Vaccines for Children Program.
The nation’s RSV rate doubled from about 5% to 10% in one month, and children’s hospitals are feeling the strain. In Texas, the emergency department at Fort Worth Cook Children’s is seeing 500 patients a day with RSV and other respiratory viruses.
The fill rate of antibiotics for bacterial infections associated with RSV increased from 1.04% to 1.42%...
Today's Sponsors
Today's Sponsor